These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8050312)

  • 1. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.
    Bernstein CN; Artinian L; Anton PA; Shanahan F
    Dig Dis Sci; 1994 Aug; 39(8):1638-41. PubMed ID: 8050312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.
    Lewis JD; Abramson O; Pascua M; Liu L; Asakura LM; Velayos FS; Hutfless SM; Alison JE; Herrinton LJ
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1195-201; quiz 1141-2. PubMed ID: 19631285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
    Connell WR; Kamm MA; Ritchie JK; Lennard-Jones JE
    Gut; 1993 Aug; 34(8):1081-5. PubMed ID: 8174958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
    Broekman MMTJ; Coenen MJH; van Marrewijk CJ; Wanten GJA; Wong DR; Verbeek ALM; Klungel OH; Hooymans PM; Guchelaar HJ; Scheffer H; Derijks LJJ; de Jong DJ;
    Inflamm Bowel Dis; 2017 Oct; 23(10):1873-1881. PubMed ID: 28644183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists.
    Wallace TM; Veldhuyzen van Zanten SJ
    Can J Gastroenterol; 2001 Jan; 15(1):21-8. PubMed ID: 11173323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.
    Meijer B; Kreijne JE; van Moorsel SAW; Derijks LJJ; Bouma G; Mulder CJJ; Wong DR; van der Woude CJ; van Bodegraven AA; de Boer NKH
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1183-1190. PubMed ID: 27859568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
    Gupta P; Gokhale R; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):450-4. PubMed ID: 11698762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease.
    Disanti W; Rajapakse RO; Korelitz BI; Panagopoulos G; Bratcher J
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1025-9. PubMed ID: 16765651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.
    Achkar JP; Stevens T; Easley K; Brzezinski A; Seidner D; Lashner B
    Inflamm Bowel Dis; 2004 Jul; 10(4):339-45. PubMed ID: 15475740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of WBC differential when leukopenia is induced by 6-MP for IBD.
    Korelitz BI; Zlatanic J; Smith MJ; Lipe RJ; Baiocco PJ; Gleim GW
    Gastroenterology; 1997 Nov; 113(5):1810-1. PubMed ID: 9352894
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
    Dubinsky MC; Lamothe S; Yang HY; Targan SR; Sinnett D; Théorêt Y; Seidman EG
    Gastroenterology; 2000 Apr; 118(4):705-13. PubMed ID: 10734022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
    Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
    Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
    Grossman AB; Noble AJ; Mamula P; Baldassano RN
    Inflamm Bowel Dis; 2008 Jun; 14(6):750-5. PubMed ID: 18266236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
    Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A coding variant in
    Kim HS; Cheon JH; Jung ES; Park J; Aum S; Park SJ; Eun S; Lee J; Rüther U; Yeo GSH; Ma M; Park KS; Naito T; Kakuta Y; Lee JH; Kim WH; Lee MG
    Gut; 2017 Nov; 66(11):1926-1935. PubMed ID: 27558924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
    Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate.
    Taguchi J; Saijo N; Miura K; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sakurai M; Minato K; Fujiwara Y
    Jpn J Cancer Res; 1987 Sep; 78(9):977-82. PubMed ID: 3117753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
    Kim JH; Cheon JH; Kim WH
    Korean J Gastroenterol; 2008 May; 51(5):291-7. PubMed ID: 18516013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.